LENZ vs. NAMS, TWST, EWTX, IBRX, MLTX, BEAM, VCEL, CNTA, DNLI, and KYMR
Should you be buying LENZ Therapeutics stock or one of its competitors? The main competitors of LENZ Therapeutics include NewAmsterdam Pharma (NAMS), Twist Bioscience (TWST), Edgewise Therapeutics (EWTX), ImmunityBio (IBRX), MoonLake Immunotherapeutics (MLTX), Beam Therapeutics (BEAM), Vericel (VCEL), Centessa Pharmaceuticals (CNTA), Denali Therapeutics (DNLI), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry.
LENZ Therapeutics vs.
LENZ Therapeutics (NASDAQ:LENZ) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.
LENZ Therapeutics has higher earnings, but lower revenue than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.
54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 38.4% of LENZ Therapeutics shares are held by insiders. Comparatively, 19.5% of NewAmsterdam Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, LENZ Therapeutics had 24 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 28 mentions for LENZ Therapeutics and 4 mentions for NewAmsterdam Pharma. LENZ Therapeutics' average media sentiment score of 0.70 beat NewAmsterdam Pharma's score of 0.66 indicating that LENZ Therapeutics is being referred to more favorably in the media.
NewAmsterdam Pharma received 14 more outperform votes than LENZ Therapeutics when rated by MarketBeat users. However, 100.00% of users gave LENZ Therapeutics an outperform vote while only 96.30% of users gave NewAmsterdam Pharma an outperform vote.
NewAmsterdam Pharma's return on equity of 0.00% beat LENZ Therapeutics' return on equity.
LENZ Therapeutics presently has a consensus target price of $41.67, suggesting a potential upside of 57.05%. NewAmsterdam Pharma has a consensus target price of $43.33, suggesting a potential upside of 93.37%. Given NewAmsterdam Pharma's higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than LENZ Therapeutics.
LENZ Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of -0.04, meaning that its share price is 104% less volatile than the S&P 500.
Summary
LENZ Therapeutics beats NewAmsterdam Pharma on 10 of the 17 factors compared between the two stocks.
Get LENZ Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LENZ Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:LENZ) was last updated on 3/28/2025 by MarketBeat.com Staff
Buy LENZ Stock Free LENZ Stock Alerts